Literature DB >> 6822834

Cimoxatone is a reversible tight-binding inhibitor of the A form of rat brain monoamine oxidase.

C J Fowler, M Strolin Benedetti.   

Abstract

Cimoxatone is a fully reversible inhibitor selective for the A form of monoamine oxidase. The inhibition is so potent against this enzyme form that it acts as a tight-binding inhibitor. Use of this inhibitor indicates that in rat brain homogenates the concentration of monoamine oxidase A is approximately 8-11 pmol . mg protein-1. Values similar to this were obtained by clorgyline titration, and both methods gave values similar to those found with a [3H]harmaline binding assay.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6822834     DOI： 10.1111/j.1471-4159.1983.tb11312.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN： 0022-3042            Impact factor:   5.372


  8 in total

Review 1.  90 years of monoamine oxidase: some progress and some confusion.

Authors:  Keith F Tipton
Journal:  J Neural Transm (Vienna)       Date:  2018-04-10       Impact factor: 3.575

2.  Estimation of the elimination half-life of the monoamine oxidase inhibitor cimoxatone in rat brain on the basis of ex vivo inhibition data.

Authors:  C J Fowler; M Strolin Benedetti; V Rovei
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1983 Oct-Dec       Impact factor: 2.441

3.  Rhesus monkey cerebrospinal fluid amine metabolite changes following treatment with the reversible monoamine oxidase type-A inhibitor cimoxatone.

Authors:  N A Garrick; T Seppala; M Linnoila; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

4.  The deamination of noradrenaline and 5-hydroxytryptamine by rat brain and heart monoamine oxidase and their inhibition by cimoxatone, toloxatone and MD 770222.

Authors:  M Strolin Benedetti; T Boucher; C J Fowler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-08       Impact factor: 3.000

5.  On the reversibility of reversible MAO inhibitors.

Authors:  P C Waldmeier
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-05       Impact factor: 3.000

6.  Short-acting novel MAO inhibitors: in vitro evidence for the reversibility of MAO inhibition by moclobemide and Ro 16-6491.

Authors:  H H Keller; R Kettler; G Keller; M Da Prada
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-01       Impact factor: 3.000

Review 7.  Assessment of Enzyme Inhibition: A Review with Examples from the Development of Monoamine Oxidase and Cholinesterase Inhibitory Drugs.

Authors:  Rona R Ramsay; Keith F Tipton
Journal:  Molecules       Date:  2017-07-15       Impact factor: 4.411

8.  IC50-to-Ki: a web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding.

Authors:  R Z Cer; U Mudunuri; R Stephens; F J Lebeda
Journal:  Nucleic Acids Res       Date:  2009-04-24       Impact factor: 16.971
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.